Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allografts Clear all
Completed No phase listed Observational

Vascular CT Assessment of Structural Autograft and Allograft Healing

NCT00594776
View directory record Official record
Conditions
Bone Tumors
Interventions
Cone Beam CT Scan
Device
Lead sponsor
University of Rochester
Other
Eligibility
10 Years to 100 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2016 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 2 Interventional

Filgrastim-Treated Donor Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia</p>

NCT00025545
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2010 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for Renal Graft Inflammation

NCT02108600
View directory record Official record
Conditions
Late Complication From Kidney Transplant
Interventions
Tocilizumab
Drug
Lead sponsor
Flavio Vincenti
Other
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Oct 22, 2026, 6:05 AM EDT
Completed No phase listed Observational

BIIR Gene to Manage Heart Allograft Patients

NCT01929785
View directory record Official record
Conditions
Cardiac Transplant Failure
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 73 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Reducing the Risk of Transplant Rejection: Simultaneous Kidney and Bone Marrow Transplant

NCT00063817
View directory record Official record
Conditions
End-stage Renal Disease, Renal Transplantation, Kidney Transplantation
Interventions
Conditioning Regimen
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure

NCT00223678
View directory record Official record
Conditions
Kidney Transplant
Interventions
Rapamycin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Alveolar Ridge Preservation With Putty Allograft vs. Putty Alloplast Graft

NCT05484492
View directory record Official record
Conditions
Alveolar Bone Resorption
Interventions
demineralized and mineralized combination putty bone allograft, calcium phosphosilicate putty alloplast graft
Biological
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 22, 2026, 6:05 AM EDT
Not listed Phase 2 Interventional

An Amniotic Membrane Injection Comparing Two Doses (1 mL and 2 mL Injection) and a Placebo (Sterile Saline) in the Treatment of Osteoarthritis of the Knee

NCT04612023
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Acellular Amniotic Membrane Derived Allograft Injection (NuDYN)
Other
Lead sponsor
Illinois Center for Orthopaedic Research and Education
Other
Eligibility
21 Years to 80 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Westmont, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 22, 2026, 6:05 AM EDT
Completed No phase listed Observational

Study of Tolerant Kidney Transplant Recipients

NCT01338779
View directory record Official record
Conditions
Transplant Rejection, Kidney Transplantation, Renal Transplantation, Renal Transplant, Transplant Tolerance
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2015
U.S. locations
4
States / cities
Atlanta, Georgia • Bethesda, Maryland • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Islet Transplantation for Patients With Type 1 Diabetes

NCT00073281
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet transplantation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 15, 2010 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Not applicable Interventional

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

NCT02707406
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
NEOX®CORD 1K, standard of care
Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

A Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) Verses Standard of Care in Adhesive Capsulitis of the Shoulder

NCT05844930
View directory record Official record
Conditions
Adhesive Capsulitis
Interventions
Corticosteroid, ActiveMatrix, Lidocaine
Drug · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 22, 2026, 6:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Role of B Cells in Kidney Allograft Dysfunction

NCT02294032
View directory record Official record
Conditions
Kidney; Complications, Allograft, Transplantation Infection
Interventions
Immunosuppressive Agents
Drug
Lead sponsor
Loma Linda University
Other
Eligibility
2 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2023
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 22, 2026, 6:05 AM EDT
Not listed Phase 3 Interventional

Allograft Adipose Injectable for Vocal Fold Paralysis

NCT04700566
View directory record Official record
Conditions
Vocal Fold Palsy
Interventions
Renuva Allograft Adipose Matrix
Biological
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2023 · Synced Oct 22, 2026, 6:05 AM EDT
Suspended Phase 1 Interventional

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

NCT02333162
View directory record Official record
Conditions
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
Interventions
Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy, Total Marrow Irradiation, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Bone Marrow Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Horizontal Ridge Augmentation With Demineralized Bone Allograft Layered With Xenograft - a Prospective Clinical Study

NCT06342973
View directory record Official record
Conditions
Alveolar Ridge Deficiency
Interventions
Xenograft and allograft
Device
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 4 Interventional Results available

Study Evaluating A Planned Transition From Tacrolimus To Sirolimus In Kidney Transplant Recipients

NCT00895583
View directory record Official record
Conditions
Graft Rejection, Kidney Transplant, Renal Allograft Recipients, Renal Transplant
Interventions
Tacrolimus, Sirolimus
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
25
States / cities
La Jolla, California • San Francisco, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 3 Interventional Results available

EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection

NCT00105183
View directory record Official record
Conditions
Chronic Obstructive Pulmonary, Idiopathic Pulmonary Fibrosis, Cystic Fibrosis, Bronchiectasis, Pulmonary Vascular Disease
Interventions
Placebo, EZ-2053, EZ-2053 5mg/kg
Biological
Lead sponsor
Neovii Biotech
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2012 · Synced Oct 22, 2026, 6:05 AM EDT
Not yet recruiting Not applicable Interventional

Allograft vs. Autograft Nonunion

NCT07310082
View directory record Official record
Conditions
Nonunion Fracture
Interventions
Autograft, Allograft
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the CR Plug for Repair of Defects Created at the Harvest Site From an Autograft in the Knee.

NCT00821873
View directory record Official record
Conditions
Knee Injury
Interventions
CR Plug
Other
Lead sponsor
RTI Surgical
Industry
Eligibility
18 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Birmingham, Alabama • Phoenix, Arizona • Englewood, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Oct 22, 2026, 6:05 AM EDT
Not listed Phase 4 Interventional

Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance Following Keloid Scar Revision Surgery

NCT02521402
View directory record Official record
Conditions
Keloid Scar
Interventions
Biovance
Biological
Lead sponsor
Golla Center for Plastic Surgery
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 1 Interventional

Tolerance by Engaging Antigen During Cellular Homeostasis

NCT03504241
View directory record Official record
Conditions
Kidney Transplantation, Renal Transplantation, Renal Transplant Recipient
Interventions
Donor-derived Mesenchymal Stromal Cells, alemtuzumab, belatacept, sirolimus, mycophenolate mofetil, mycophenolate acid, prednisone
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 6:05 AM EDT
Completed Phase 2 Interventional Results available

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00119392
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Interventions
rituximab, cyclosporine, fludarabine phosphate, mycophenolate mofetil, yttrium Y 90 ibritumomab tiuxetan, peripheral blood stem cell transplantation, allogeneic hematopoietic stem cell transplantation, total-body irradiation
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 22, 2026, 6:05 AM EDT
Terminated Phase 2 Interventional Results available

Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma

NCT00505921
View directory record Official record
Conditions
Lymphoma
Interventions
Campath-1H, G-CSF, GM-CSF, BCNU, Stem Cell Transplant, Preparative Regimen for Allogenic Stem Cell Transplantation, Cytarabine, Etoposide, Melphalan, Campath, Fludarabine, Cyclophosphamide, Low dose total body irradiation
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 22, 2026, 6:05 AM EDT